SCHEMBL5042607

SCHEMBL5042607

CCOC(=O)C(OCC)c1c(F)cc(OC)cc1F

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.40
HPGD P15428 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.38
PRKCZ Q05513 1/20 0.38
ALDH1A1 P00352 2/20 0.38
MAPK1 P28482 2/20 0.38
TSHR P16473 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
KMT2A Q03164 3/20 0.37
GAA P10253 1/20 0.37
TAAR1 Q96RJ0 1/20 0.37
NPC1 O15118 1/20 0.36
HTT P42858 1/20 0.36
MEN1 O00255 1/20 0.36
PKM P14618 1/20 0.36
GLA P06280 1/20 0.35
MTNR1B P49286 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5042882 0.89 PTGS2 (0.41) HPGDPRKCZALDH1A1MAPK1TSHR
SCHEMBL5038048 0.86 PTGS2 (0.39) CYP3A4HPGDKMT2ATAAR1
SCHEMBL5047314 0.86 MAPK1 (0.47) ALDH1A1MAPK1TSHRTDP1L3MBTL1
SCHEMBL5042392 0.84 CA12 (0.42) CYP3A4HPGDSMN1; SMN2TDP1GAA
SCHEMBL1462180 0.83 CYP3A4 (0.43) CYP3A4HPGDSMN1; SMN2PRKCZALDH1A1
SCHEMBL5042724 0.82 HIF1A (0.38) HPGDSMN1; SMN2ALDH1A1MAPK1KMT2A
SCHEMBL5043173 0.82 CYP2C9 (0.39) MAPK1KMT2ANPC1HTTMEN1
SCHEMBL5042739 0.81 SMN1; SMN2 (0.43) CYP3A4HPGDSMN1; SMN2PRKCZALDH1A1
SCHEMBL5040728 0.81 PRKCZ (0.44) HPGDPRKCZALDH1A1MAPK1TSHR
SCHEMBL5040727 0.81 PRKCZ (0.44) HPGDPRKCZALDH1A1MAPK1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1567498-B1 MANDELIC ACID DERIVATIVES HOFFMANN LA ROCHE (CH) 2008-01-23 EP disclosed
US-7129238-B2 Mandelic acid derivatives HOFFMANN-LA ROCHE INC. (US) 2006-10-31 US disclosed
EP-1567498-A2 MANDELIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2005-08-31 EP disclosed
US-20040122057-A1 Novel mandelic acid derivatives HOFFMANN-LA ROCHE INC. 2004-06-24 US disclosed
WO-2004048335-A2 MANDELIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2004-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122057-A1 Novel mandelic acid derivatives F7, F11, F9 CYP3A4 1458/4885HPGD 2678/4885SMN1; SMN2 3242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.